Abstract
The America Invents Act (AIA) will affect how intellectual property rights for pharmaceutical innovations are obtained, challenged and enforced. For example, the AIA allows pharmaceutical companies to take a more uniform approach in seeking patent protection worldwide. Post-grant and inter partes review procedures in the USPTO will allow patents to be challenged by pharmaceutical interests at a lower cost than that of litigation in US courts, and should improve the quality of patents as a whole. Provisions in the AIA incentivize pharmaceutical companies to monitor the published applications and patents of competitors, and to make prompt challenges to patentability where appropriate, promoting the integrity of the intellectual property landscape.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
